The evolutionarily conserved DOCK180 protein has an indispensable role in cell migration by functioning as an exchange factor for Rac GTPase via its DOCK homology region (DHR)-2 domain. We report here that the conserved DHR-1 domain also has an important signalling role. A form of DOCK180 that lacks DHR-1 fails to promote cell migration, although it is capable of inducing Rac GTP-loading. The DHR-1 domain interacts with PtdIns(3,4,5)P 3 in vitro and in vivo, and mediates the DOCK180 signalling complex localization at sites of PtdIns(3,4,5)P 3 accumulation in the cell's leading edge. A form of DOCK180 in which the DHR-1 domain has been replaced by a canonical PtdIns(3,4,5)P 3 -binding pleckstrin homology domain is fully functional at inducing cell elongation and migration, suggesting that the main function of DHR-1 is to bind PtdIns(3,4,5)P 3 . These results demonstrate that DOCK180, via its DHR-1 and DHR-2 domains, couples PtdIns(3,4,5)P 3 signalling to Rac GTP-loading, which is essential for directional cell movement.
The key response of a cell to a migratory attractant is to extend membrane protrusions in the direction of migration. This polarization is triggered by the recruitment of phosphatidylinositol (PtdIns) 3-kinases to the cellular sites that initially sense the attractant 1, 2 . PtdIns(3,4,5)P 3 subsequently accumulates at the leading edge while it is being degraded at the rear of the cell by PTEN-like activity, resulting in a PtdIns(3,4,5)P 3 gradient at the membrane [3] [4] [5] [6] . PtdIns(3,4,5)P 3 accumulation is followed by the recruitment of lipid-binding proteins that promote actin-based membrane protrusions at the leading edge 1 . Rho GTPases, such as Rac, have a key role in orchestrating the cytoskeletal rearrangements necessary for cell migration 7 . When in an active GTP-bound form, Rho GTPases couple to their effectors to induce specific biological outputs. Rac is preferentially activated at the leading edge where it induces membrane extensions, in part, through the WAVE-Arp2/3 complex 8 . At present, the signalling mechanisms that facilitate localized Rac activation are not understood.
Mammalian DOCK180 was originally identified as a major binding partner for the Crk adaptor protein 9 . Subsequent genetic studies demonstrated that the DOCK180 orthologues Myoblast city and CED-5 in Drosophila melanogaster and Caenorhabditis elegans, respectively, have a crucial role in regulating Rac signalling in processes such as myoblast fusion, cell migration and phagocytosis [10] [11] [12] [13] [14] . Studies in C. elegans have further identified CED-12 (ELMO) as an upstream regulator of Rac that functions genetically at the same step as DOCK180 (refs 15-17) . In mammalian cells, the Crk-ELMO-DOCK180 complex activates several Rac-dependent pathways, including the JNK kinase cascade, actin remodelling, cell migration and engulfment of apoptotic cells 15, [17] [18] [19] [20] . Recent work by us and others has identified an evolutionarily conserved DOCK180-related protein superfamily, several members of which are guanine nucleotide-exchange factors (GEFs) of Rho GTPases 21, 22 . In accordance with the genetic studies, DOCK180 functions as a specific GEF for Rac 21, 23 . The DOCK180 family members lack a discernable tandem Dbl homology (DH)-pleckstrin homology (PH) domain, which is the hallmark catalytic domain of the canonical Rho-GEFs. Instead, they rely on a DHR-2 (also known as CZH2 or DOCKER) domain that, similar to the DH-PH module, interacts with a nucleotide-free GTPase and promotes its activation [21] [22] [23] . We have previously identified another evolutionarily conserved domain, termed DHR-1 (also known as CZH1), in all known members of the DOCK180 superfamily 21, 22 . Here, we report that the DHR-1 domain is a novel PtdIns(3,4,5)P 3 -binding module, which localizes the DOCK180 signalling complex to the leading edge and is crucial for DOCK180-mediated cell elongation and cell migration.
RESULTS

The DHR-1 domain is required for DOCK180-induced cell elongation and motility
The significance of the DHR-1 domain in DOCK180-mediated signalling was examined by expressing DOCK180 with a deletion of the DHR-1 domain (DOCK180∆DHR-1; see Supplementary Information, Fig. S1 ) in LR73 cells (a CHO cell variant commonly used for cell spreading and migration studies) 15, 23, 24 . As shown in Fig. 1a , control-transfected cells spread and assembled actin stress fibres on fibronectin. Cells that had been transfected with wild-type DOCK180 or ELMO1 alone, or DOCK180 and ELMO1 together, were morphologically indistinguishable from the control cells (data not shown). As reported previously 15 , expression of CrkII alone or CrkII together with DOCK180 or ELMO1 resulted in membrane ruffling (data not shown). Upon coexpression of DOCK180, ELMO and CrkII, more than 40% of the cells adopted a highly elongated morphology (Fig. 1a) . Thus, simultaneous expression of CrkII, ELMO and DOCK180 is required for an extended cellular morphology, reflecting the in vivo finding that all three gene products are indispensable in C. elegans for processes such as cell migration. Notably, cells expressing DOCK180∆DHR-1, ELMO1 and CrkII failed to acquire an elongated morphology (Fig. 1a) . Furthermore, a strong correlation was observed between the elongated phenotype and cell migration. Only when DOCK180, ELMO1 and CrkII were expressed together, was a highly significant, sevenfold increase in cell migration observed (Fig. 1c,  d ). Cells coexpressing DOCK180∆DHR-1, ELMO1 and CrkII failed to exhibit significantly enhanced motility, demonstrating that the DHR-1 domain is essential for DOCK180-mediated directional cell movement.
In a reverse experiment, downregulation of DOCK180 by siRNA resulted in a reduction in the number of fully spread cells (70% of the cells are fully spread on fibronectin upon control siRNA treatment versus 54% upon DOCK180 siRNA treatment; Fig. 2a-c) . Notably, re-expression of the wild-type DOCK180 protein in DOCK180 siRNA-treated cells significantly rescued the spread morphology and assembly of actin stress fibres (71% of the cells are spread; Fig. 2b, c) . In contrast, the DOCK180∆DHR-1 mutant failed to rescue the spread phenotype (47% of the cells are spread; Fig. 2b, c) . Because total pools of transfected cells were analysed in these studies, we also performed immunofluorescence analysis of individual transfected cells and similar results were obtained (Fig. 2d, e) . Fifty-seven per cent of DOCK180 siRNA-treated cells reexpressing high levels of DOCK180 showed a fully spread morphology, whereas 60% of the DOCK180 siRNA-treated cells expressing equally high levels of the DOCK180∆DHR-1 protein remained round (Fig. 2d , e). Taken together, these studies support the notion that the DHR-1 domain has an essential role in DOCK180 signalling.
Impaired signalling by the DHR-1 mutant of DOCK180 is not due to reduced Rac GTP-loading
The failure of DOCK180∆DHR-1 to promote cell elongation and cell migration raised the possibility that ablating the DHR-1 domain could impair the ability of DOCK180 to induce Rac GTP-loading. This was not found to be the case, as DOCK180∆DHR-1 was able to promote Rac GTP-loading to the same extent as wild-type DOCK180 both in the presence and absence of ELMO1 and CrkII (Fig. 3a) . As previously reported 21 , the DHR-2 domain was found to be essential for DOCK180-mediated Rac GTP-loading (Fig. 3a) . We found that the inability of Cell migration (cells per field)
Figure 1
The DHR-1 domain is required for DOCK180-mediated cell elongation and motility. (a) Serum-starved LR73 cells that had been transfected with the indicated plasmids were detached and plated on fibronectin-coated coverslips for 2 h in the absence of serum prior to fixing. Cells in the left panels were stained with anti-DOCK180 (H-4), whereas the panels on the right represent an overlay of the anti-DOCK180, rhodamine-phalloidin and DAPI stains. Cells were photographed at ×60 magnification. Scale bar, 15 µm. (b) Expression levels of the transfected proteins were analysed by immunoblotting of cell lysates with anti-DOCK180 (C-19) and anti-Myc antibodies, as indicated. (c, d) Serumstarved LR73 cells that had been transfected with a GFP plasmid together with the indicated plasmids were detached and placed in the upper compartment of a Boyden chamber. In the haptotactic migration assay (c), the cells were allowed to migrate for 4 h towards fibronectin. In the chemotactic assay (d), the top and bottom sides of the membrane were pre-coated with fibronectin and the cells were allowed to migrate for 4 h towards 10% serum as a chemoattractant in the lower chamber. Cells were fixed and stained with DAPI. GFP/DAPI double-positive cells that had migrated across the membrane were counted from photographs taken at ×40 magnification. The experiments described above were performed independently three times in duplicate. Data are shown as mean ± s.d. *P < 0.001; one-way ANOVA. WT, wild type. (e) Expression levels of the transfected proteins were analysed by immunoblotting of cell lysates with anti-DOCK180 (C-19) and anti-Myc antibodies, as indicated. DOCK180∆DHR-1 to promote cell elongation and cell migration is not a consequence of a failure to interact with its binding partners either, as DOCK180∆DHR-1 was found to associate with CrkII and ELMO1 to the same extent as wild-type DOCK180 in coimmunoprecipitation experiments (Fig. 3b) .
The DHR-1 domain of DOCK180 binds PtdIns(3,5)P 2 and PtdIns(3,4,5)P 3 We previously noted a putative C2 domain in the DHR-1 region of DOCK180 by SMART analysis 21 . C2 domains mediate non-specific binding to anionic phospholipids such as phosphatidylserine in a Ca 2+ -regulated (type I topology) or non-regulated (type II topology) manner 25 . In rare instances, C2 domains can interact with both phosphoinositides and proteins [25] [26] [27] [28] . The lipid-binding activity of C2 domains resides in three loops (CBR1-3) that are enriched in basic amino acids, and we noticed such clusters of conserved basic amino acids in the putative CBR1 and CBR3 loops in the DHR-1 domain (see Supplementary  Information, Fig. S1 ). We therefore decided to investigate whether the DHR-1 domain interacts with lipids, and focused on phosphoinositides due to their known role in cell migration. When incubated with beads coated with various phosphoinositides, the DHR-1 domain interacted specifically with PtdIns(3,5)P 2 and PtdIns(3,4,5)P 3 (Fig. 4a) . Similar binding was observed in the presence of either 1.1 mM Ca 2+ or 5 mM EDTA, suggesting that the interaction is not Ca 2+ -regulated (data not shown). In a control experiment, the PH domain of Akt was specifically precipitated by PtdIns(3,4,5)P 3 beads 29 ( Fig. 4a) . Sequential truncations in the carboxyl terminus of the DHR-1 domain demonstrated that the minimal lipid-binding site encompassed residues 422-619, the boundaries of the putative C2 domain being residues 422-587 (Fig. 4b) .
A liposome competition assay demonstrated that the binding between the DHR-1 domain and the PtdIns(3,4,5)P 3 beads is specific. Pre-incubation of DHR-1 with phosphatidylserine (PS) liposomes containing 8 µM PtdIns(3,5)P 2 inhibited the binding of DHR-1 to the PtdIns(3,5)P 2 beads by approximately 80% (Fig. 4c) , and this effect was dose dependent (data not shown). Liposomes of PS alone, PS containing either 8 µM PtdIns or PtdIns(4,5)P 2 , or Ins(1,3,4,5)P 4 did not significantly compete with the DHR-1 binding. In a control experiment, PS:PtdIns(3,4,5)P 3 liposomes specifically disrupted the binding of the PH domain of Akt to the PtdIns(3,4,5)P 3 beads (Fig. 4c) .
A mutant form of DHR-1 with a predicted loss of function in the PtdIns(3,4,5)P 3 -binding activity was generated. The mutated residues were selected on the basis of sequence alignment between the DHR-1 domains of the DOCK180 superfamily (see Supplementary Information,  Fig. S1 ), and between the DOCK180 DHR-1 domain and the C2 domain of PtdIns 3-kinase γ (data not shown). In the construct DHR-1(6K/A), six lysines, three each in the putative CBR1 and CBR3 loops, were mutated to alanine (see Methods). We hypothesized that these positively charged residues were directly involved in coordinating PtdIns(3,4,5)P 3 . When subjected to a pull-down with the PtdIns(3,4,5)P 3 beads, DHR-1(6K/A) exhibited little lipid-binding activity (Fig. 4d) . A negative control -the focal adhesion targeting (FAT) domain of focal adhesion kinase (FAK) 30 -similarly failed to interact with the PtdIns(3,4,5)P 3 beads. Notably, cells expressing a full-length form of DOCK180 in which the same six lysines had been mutated to alanine -DOCK180(6K/A) -together with ELMO1 and CrkII, failed to exhibit an elongated morphology (see Supplementary Information, Fig. S2 ).
Lipid-blot overlay assays 31 were performed to confirm the PtdIns(3,4,5)P 3 -binding activity of the DHR-1 domain. In agreement with the bead data, the wild-type form of the DHR-1 domain readily interacted with PtdIns(3,4,5)P 3 , whereas the DHR-1(6K/A) failed to do so. In control experiments, the PH domain of Akt 29 and the tail domain of vinculin 32 interacted with PtdIns(3,4,5)P 3 and PtdIns(4,5)P 2 , respectively ( Fig. 4e) . Taken together, these data suggest that the DHR-1 domain is a lipid-binding module that is necessary for DOCK180 function. The DHR-1 domain mediates DOCK180 membrane translocation in response to PtdIns(3,4,5)P 3 production Several lines of investigation were undertaken to examine the role of the DHR-1 domain in lipid binding in cells, as well as the significance of PtdIns(3,4,5)P 3 in DOCK180 signalling. First, clarified lysates of cells expressing either the wild-type DOCK180 or the DOCK180∆DHR-1 mutant were subjected to a pull-down by the PtdIns(3,4,5)P 3 beads. Whereas the wild-type DOCK180 protein readily interacted with the beads, DOCK180∆DHR-1 was only weakly precipitated in this assay (Fig. 5a ). These data suggest that most of the PtdIns(3,4,5)P 3 -binding activity of DOCK180 can be attributed to the DHR-1 domain. We next investigated whether the endogenous DOCK180 protein would translocate to the membrane in response to PtdIns 3-kinase activation. DOCK180 was readily recruited to the membrane in NIH3T3 cells that had been treated with platelet-derived growth factor (PDGF) to activate PtdIns 3-kinase 33 . Notably, this membrane recruitment was blocked by pre-treatment of the cells with the PtdIns 3-kinase inhibitor LY294002 (Fig. 5b) . The importance of the DHR-1 domain for DOCK180 membrane translocation was subsequently addressed. As an experimental system, an active form of PtdIns 3-kinase, p110* (ref. 34) , was used to induce PtdIns(3,4,5)P 3 production. The wildtype DOCK180 protein was primarily localized in the cytosol when expressed alone (Fig. 5c ). When coexpressed with p110*, it readily localized to the membrane fraction. This translocation was found to be dependent on the DHR-1 domain, because the DOCK180∆DHR-1 protein remained cytosolic both in the presence and absence of p110*. As a control for fractionation, p110* was found exclusively in the cytosolic fraction, in agreement with the reported localization of this mutant protein 34 ( Fig. 5c ). These results demonstrate that the DHR-1 domain is critical in mediating PtdIns 3-kinase-dependent translocation of DOCK180 to the cell membrane.
LY294002 was also used to examine the importance of PtdIns(3,4,5)P 3 in DOCK180-induced cell elongation and migration. As shown in Fig. 6a , cells expressing DOCK180, ELMO1 and CrkII that had been treated with LY294002 failed to adopt an elongated phenotype when plated on fibronectin (compare with Fig. 1a) . LY294002 also abrogated the ability of the CrkII-ELMO-DOCK180 complex to promote significant cell movement, as shown in Fig. 6b . These findings further support the role of PtdIns(3,4,5)P 3 in CrkII-ELMO-DOCK180 signalling. (bottom panels). Cells were subsequently left untreated (top panels) or stimulated with 10 ng ml −1 PDGF (middle and bottom panels) for 10 min prior to fixing. Cells in the left panels were stained with an anti-DOCK180 rabbit polyclonal antibody, whereas the panels on the right represent an overlay of the anti-DOCK180, rhodamine-phalloidin and DAPI stains. Cells were photographed at ×60 magnification. Scale bar 20 µm. (c) DOCK180 translocates to the membrane in response to PtdIns(3,4,5)P 3 production in a DHR-1-dependent manner. HEK293T cells were transfected with the indicated plasmids. After 24 h, the cytosolic and membrane fractions were biochemically purified and the distribution of DOCK180, DOCK180∆DHR-1 and p110* was analysed by immunoblotting with the indicated antibodies.
The CrkII-ELMO1-DOCK180 complex is enriched in membrane extensions and colocalizes with PtdIns(3,4,5)P 3 We next investigated whether the CrkII-ELMO-DOCK180 complex localizes to sites of membrane extensions by coexpression of differentially tagged forms of DOCK180, CrkII and ELMO. In sequential coimmunoprecipitation experiments, we first observed that more than 90% of both endogenous and exogenously expressed ELMO and DOCK180 proteins are found in the same complex (see Supplementary Information, Fig. S2) . Thus, the localization of green fluorescent protein (GFP)-ELMO1 or red fluorescent protein (RFP)-ELMO1 was subsequently used as a marker for the CrkII-ELMO-DOCK180 complex in cells. As shown in a timelapse analysis (see Supplementary Information, Movie S1 and Fig. S3 ), GFP-ELMO was enriched in membranes undergoing dynamic rearrangements during cell elongation on fibronectin. Once the leading edge had been established (see Supplementary Information, Fig. S3 ; t = 14 min), less membrane ruffling, and localization of ELMO1 at the leading edge, was observed. Similarly, transfected DOCK180 localized at the leading edge in membrane ruffles of cells that had been allowed to spread for 60 min on fibronectin (see Supplementary Information, Fig. S2 ), but once the leading edge had been established, less localization of DOCK180 at the membrane ruffles was observed (Fig. 1a and data not shown) .
To examine whether the CrkII-ELMO-DOCK180 complex colocalizes with PtdIns(3,4,5)P 3 at the leading edge, Flag-tagged DOCK180, Myctagged CrkII and RFP-tagged ELMO1 were coexpressed with the GFPtagged PH domain of BTK, a validated in vivo probe for PtdIns(3,4,5)P 3 . COS-7 cells were chosen in this experiment to allow the use of epidermal growth factor (EGF) as a positive control for the recruitment of the PH domain of BTK to the membrane. As shown in a time-lapse movie (see Supplementary Information, Movie S2 and Fig. S3) , colocalization of the RFP-ELMO1 protein and the GFP-BTK-PH domain was observed in membrane ruffles at the leading edge upon cell elongation on fibronectin for 1 h. When the same cell was subsequently stimulated with EGF for 10 min, membrane ruffling occurred randomly throughout the cell, leading to colocalization of RFP-ELMO1 and GFP-BTK-PH at these sites. These results suggest that the CrkII-ELMO-DOCK180 complex localizes to PtdIns(3,4,5)P 3 accumulation sites, which agrees with our biochemical data, demonstrating that DOCK180 translocates to the membrane in response to PtdIns(3,4,5)P 3 generation.
A PH domain with PtdIns(3,4,5)P 3 -binding activity can functionally replace the DHR-1 domain in DOCK180
To determine whether the main function of the DHR-1 domain of DOCK180 during cell elongation and migration is to interact with PtdIns(3,4,5)P 3 , we generated a DOCK180 construct in which the DHR-1 domain was replaced with the PtdIns(3,4,5)P 3 -binding PH domain of the BMX/Etk tyrosine kinase 35 (see Supplementary Information, Fig. S1 ). In control experiments, we found that both the isolated PH domain of BMX/Etk and the chimeric DOCK180∆DHR-1 + PH protein bound to beads coated with PtdIns(3,4,5)P 3 ( Fig. 5a and see Supplementary  Information, Fig. S4 ). We also confirmed that DOCK180∆DHR-1 + PH promoted Rac GTP-loading and CrkII-ELMO-DOCK180 complex formation to the same extent as wild-type DOCK180 (see Supplementary  Information, Fig. S4 ). Additionally, coexpression of p110* resulted in translocation of DOCK180∆DHR-1 + PH -similarly to wild-type DOCK180 -to the membrane compartment (Fig. 7a) .
In subsequent functional studies, we found that when coexpressed with ELMO1 and CrkII, DOCK180∆DHR-1 + PH was capable of promoting cell elongation (Fig. 7b) . Furthermore, cell extension promoted by DOCK180∆DHR-1 + PH was sensitive to PtdIns 3-kinase inhibition (Fig. 7b) . Cells expressing DOCK180∆DHR-1 + PH were morphologically indistinguishable from the cells expressing wild-type DOCK180. Quantitatively, we found that approximately 42% of the cells expressing wild-type DOCK180 and 29% of the cells expressing the PH domain chimaera had an elongated morphology, whereas only 4% of the DOCK180∆DHR-1-transfected cells showed this phenotype (Fig. 7c) . As shown in Fig. 7d , e, the DOCK180∆DHR-1 + PH protein was found to fully recapitulate the function of the wild-type DOCK180 protein both in haptotactic and chemotactic migration assays. These results demonstrate CrkII-ELMO1-DOCK180-induced cell migration is sensitive to LY294002. Serum-starved LR73 cells expressing the indicated plasmids, together with a plasmid for GFP, were subjected to a haptotactic migration assay. For the sample treated with 25 µM of LY294002, the inhibitor was added to both the upper and the lower compartment of the modified Boyden chamber. Cell migration was analysed as described in Fig. 1a . Data represent mean ± s.d. of a representative experiment performed in duplicate. *P < 0.001; one-way ANOVA. In the right panel, expression levels of the transfected proteins were analysed by immunoblotting of cell lysates with anti-DOCK180 (C-19) and anti-Myc antibodies, as indicated.
that a canonical PtdIns(3,4,5)P 3 -binding domain can functionally replace the DHR-1 domain during DOCK180-mediated cell elongation and cell migration. These results also support our conclusion that the role of the DHR-1 domain, via PtdIns(3,4,5)P 3 binding, is to couple PtdIns 3-kinase signalling to the regulation of the CrkII-ELMO-DOCK180 complex in processes that require localized Rac activation at sites of membrane extensions, such as cell motility. . We report here that another conserved domain in DOCK180-related proteins, DHR-1, is also indispensable for the biological function of DOCK180, because it couples the production of PtdIns(3,4,5)P 3 at the membrane to DOCK180-mediated Rac GTP-loading.
DISCUSSION
We found that forms of DOCK180 that either lack DHR-1 or contain point mutations in that domain fail to induce cell elongation and directional cell movement. The DOCK180∆DHR-1 protein was found to induce Rac GTP-loading to the same extent as the wild-type DOCK180, supporting the notion that GTP-loading of Rac alone is not sufficient to induce processes that require cell polarization 36 . Instead, it is known that formation of a PtdIns(3,4,5)P 3 gradient at the membrane mediates Rac-dependent actin reorganization at the leading edge, which is required for directional cell movement [4] [5] [6] . What had remained unclear is how PtdIns(3,4,5)P 3 integrates with DOCK180 signalling to regulate Rac function upon cell polarization. We report here that the DHR-1 domain directly binds to PtdIns(3,4,5)P 3 . Furthermore, a form of DOCK180 in which the DHR-1 domain had been replaced by a canonical PtdIns(3,4,5)P 3 -binding PH domain efficiently mediated cell elongation and cell migration. Thus, the two conserved domains in DOCK180, DHR-1 and DHR-2, function to integrate PtdIns(3,4,5)P 3 signalling with Rac GTP-loading, and this integration is essential for membrane polarization and cell migration to occur.
Our finding that DOCK180 translocates to the plasma membrane in response to PtdIns(3,4,5)P 3 production is in agreement with a report by Kobayashi et al. 37 . These authors suggested that a cluster of basic amino acids in the carboxyl terminus of DOCK180 could mediate an ionic interaction with phosphate residues of PtdIns(3,4,5)P 3 . Kobayashi et al. noted, however, that this ionic interaction is not sufficient for the binding of full-length DOCK180 to PtdIns(3,4,5)P 3 because Ins(1,3,4,5)P 4 , which inhibits an ionic interaction, cannot compete with PtdIns(3,4,5)P 3 binding to full-length DOCK180 (ref. 37 ). Thus, a region(s) other than the basic domain must participate in the recognition of PtdIns(3,4,5)P 3 and DOCK180 membrane translocation. Our studies identify the DHR-1 domain as this region because we found that it binds to PtdIns(3,4,5)P 3 in a non-ionic manner, and that it is essential for PtdIns 3-kinase-induced membrane translocation of DOCK180.
The structural basis of the DHR-1-domain-mediated PtdIns(3,4,5)P 3 binding is at present unknown. Identification of a putative C2 domain within the DHR-1 domain is interesting, but requires experimental verification. C2 domains typically interact with lipids such as phosphatidylserine and phosphatidylcholine: we failed to detect such interactions for DHR-1. Recently, the C2 domains of Jfc1 and Rsb5 proteins have been reported to bind rather promiscuously to several phosphoinositides, including PtdIns(3,4,5)P 3 (refs 26, 28) . Therefore, subsets of C2 domains are emerging as genuine phosphoinositide-binding modules. Our finding that point mutations in the putative CBR1 and CBR3 loops in the DHR-1 domain abolish both the lipid-binding activity and the function of the protein, provide supporting evidence for the presence of a C2-like domain within DHR-1. Because the sequences of the DHR-1 domain are conserved across the DOCK180-related proteins, it is plausible that the lipid-binding function is also conserved. Indeed, in vitro experiments demonstrate that several other DHR-1 domains -those of DOCK3, DOCK6 and DOCK9 (zizimin1) -also have lipid-binding activity (data not shown).
Our results and previous studies by others demonstrate that the presence of all three components of the CrkII-ELMO-DOCK180 complex is required for cell elongation and migration 15, 21, 23 . Our studies here provide a molecular explanation for the role of DOCK180 in this complex, that of coupling PtdIns(3,4,5)P 3 signalling with Rac GTP-loading. Going forward, it will be important to identify the biological events regulated by this multiprotein complex that are PtdIns(3,4,5)P 3 dependent. Also of note, our studies do not rule out the possibility that ELMO1 and CrkII could provide membrane-targeting activity. For example, it has been suggested that the PH domain of CED-12 (ELMO) is required for membrane targeting and protein function in C. elegans 17 . We have also detected lipidbinding activity in the PH domain of ELMO (data not shown), but further studies will be required to determine the specificity of this domain and the biological function of this activity. Additional work is needed to understand the full biological significance of the CrkII-ELMO-DOCK180 protein complex and its regulation in cellular signalling.
METHODS
Constructs, reagents and antibodies. Flag-tagged DOCK180 in pCNX2 and Myc-tagged CrkII in pCAGGS have been described previously 38 and were obtained from M. Matsuda. DOCK180∆DHR-2 in pcDNA3.1(Zeo r ) and Myctagged ELMO1 in pcDNA3.1 have been described in ref. 21 . pEGFP-ELMO1 (ref. 15 ) was obtained from K. Ravichandran. The pEGFP-BTK PH domain was a gift from T. Mustelin. The plasmid p110* has been described in ref. 34 and was a gift from J. Olefsky. The FAT domain of FAK in pET has been described previously 30 . The various His-DOCK180 DHR-1 constructs for bacterial expression were generated by PCR using the DOCK180 cDNA as a template, and cloned into the NdeI/BamHI site of pET28a (Novagen, Madison, WI). The DOCK180∆DHR-1 construct was generated by replacing a NotI/BglII fragment, coding for residues 1-602, of the wild-type DOCK180 in pcDNA3.1(Zeo r ) with a PCR-generated NotI/BglII fragment coding for residues 1-421 of human DOCK180. The result was an in-frame deletion of the sequences coding for residues 422-602 of DOCK180. To generate DOCK180∆DHR-1 + PH in pcDNA3.1(Zeo r ), the PH domain-coding sequences of BMX/Etk, residues 1-150 of human BMX/Etk 39 , were amplified by PCR and ligated into the BglII site of DOCK180∆DHR-1 (see above). This resulted in a construct coding for a chimeric protein in which residues 422-602 of DOCK180 were replaced by the PH domain of BMX/Etk. The PH domain of BMX/Etk was also subcloned in the bacterial expression vector pGEX4T1. The pET28 DHR-1 mutant (K439,442,446,522,524,527A) and the full-length DOCK180 with the 6K/A mutations were generated by site-directed mutagenesis (QuickChange; Stratagene; La Jolla, CA).
Fibronectin was purified from human serum as described in ref. 40 and used at a concentration of 10 µg ml −1 to coat tissue culture surfaces. The following reagents were obtained from commercial sources: LY294002 (Calbiochem, San Diego, CA); Ins(1,3,4,5)P 4 (Sigma, St Louis, MO); PtdIns(3,5)P 2 , PtdIns(3,4,5)P 3 and PIP n beads (Echelon Bioscience, Salt Lake City, UT); phosphatidylserine, phosphatidylcholine, PtdIns and PtdIns(4,5)P 2 (Avanti Polar Lipids, Alabaster, AL); anti-DOCK180 (C-19 and H-4), anti-Myc (9E10), anti-GST-HRP (Z-5) and anti-GFP (B-2) antibodies (Santa Cruz Biotechnologies, Santa Cruz, CA); monoclonal antibodies against CrkII and the p85 subunit of PtdIns 3-kinase (Pharmingen, San Diego, CA), antiHis antibody (Qiagen, Valencia, CA); polyclonal antibody against ELMO1 (Abcam, Cambridge, MA); Rac monoclonal antibody 23A8 (Upstate, Lake Placid, NY); mouse monoclonal anti-tubulin antibody Ab-1 (Calbiochem); the control and DOCK180 mouse specific siRNAs (Santa Cruz Biotechnologies); purified GST PH domain of Akt (Upstate). The recombinant vinculin tail has been described in ref. 32 and was obtained from R. Liddington. The polyclonal antibody against DOCK180 was a gift from M. Matsuda.
Cell culture and transfections. LR73 cells were maintained in alpha MEM supplemented with 10% fetal bovine serum, penicillin and streptomycin. HEK293-T, COS-7 and NIH3T3 cells were cultured in DMEM supplemented with 10% fetal serum, penicillin and streptomycin. About 750,000 LR73 cells were plated in a 6-well plate 24 h prior to transfection. For transfection, 2-2.5 µg of plasmids and 8 µl of Lipofectamine2000 (Invitrogen, Carlsbad, CA), mixed in OptiMEM media, were used as per the manufacturer' s instructions. Cells were analysed 24 h later. HEK293-T cells (1 × 10 6 ) were plated in a 6-well plate 24 h prior to transfection. The cells were transfected with up to 4 µg of plasmid DNA and 8 µl of Cytopure reagent (Q-Biogen, Irvine, CA) in OptiMEM media as per the manufacturer's instructions. Cells were analysed 24 h later. For siRNA experiments, 2.2 × 10 5 LR73 cells were seeded per well in a 12-well plate in an antibiotic-free medium. The following day, cells were cotransfected with plasmids encoding for DOCK180 (1.0 µg), DOCK180∆DHR-1 (2.0 µg) or empty vector, and 80-100 nM of siRNA against mouse DOCK180 (SC-35208) or control siRNA (SC-45037). Transfections were performed in triplicate, using 2 µl of Lipofectamine2000 (Invitrogen) and 500 µl of OptiMEM media per well, according to the manufacturer's instructions. At 18-20 h post-transfection, cells were starved in alpha-MEM containing 0.5% FBS overnight and duplicates were harvested for cell morphology assays (see below). Cells from the third well were lysed in RIPA buffer, and 15-20 µg of the cleared lysates were used for immunoblot analysis.
Immunoprecipitations and Rac-GTP assays. Cells were lysed in a buffer consisting of 25 mM Tris-HCl pH 7.5, 150 mM NaCl, 1% Triton X-100, 5 mM NaF, 0.1 mM Na 3 VO 4 and 1 × Complete protease inhibitors (Roche, Indianapolis, IN) for 10 min. Clarified cell lysates were incubated with the appropriate antibody and immune complex formation was performed for 1 h on ice. Protein A-sepharose was added for 30 min to isolate the immune complex. The beads were washed three times with lysis buffer and the bound proteins were analysed by SDS-PAGE and immunoblotting. In one experiment, we used 0.5% NP-40 and RIPA buffers to isolate the soluble and membrane-bound proteins, respectively, as described in ref. 41 . The GTP-loading status of Rac was analysed by GST PAK-PBD affinity precipitation as described previously 21 .
Cell morphology analysis and time-lapse microscopy. LR73 cells, treated with various siRNAs or transfected with the indicated plasmids, were serum-starved overnight in media supplemented with 0.5% serum. A typical transfection consisted of a total of 1.5 µg plasmid DNA (0.9 µg DOCK180, 0.3 µg ELMO1 and 0.3 µg CrkII), and, for the various experimental conditions, the amount of total plasmid was always kept constant by adding empty vector. On the day of the assay, the cells were detached and harvested in 1 × Hanks balanced salt solution supplemented with 5 mM EDTA and 0.1% trypsin, followed by one wash with Fibroblast Basal Media (FBM; Cambrex, East Rutherford, NJ) supplemented with 0.5% BSA (Sigma). Cells were resuspended in 600 µl of FBM-BSA, counted and adjusted to 1 × 10 6 cells per ml. From each sample, 100,000 cells were plated on 4-well LabTek chamber slides (Nalge Nunc International, Naperville, IL) that had been pre-coated with fibronectin (10 µg ml
−1
). The cells were allowed to spread for 2 h before fixing with 4% paraformaldehyde. The fixed material was permeabilized by incubation with PBS-0.2% Triton X-100 for 10 min followed by blocking in PBS-1% BSA for 30 min. Cells were stained with anti-DOCK180 antibody (H-4) at a 1:100 dilution in blocking buffer for 1 h. Following several PBS washes, a secondary mouse antibody coupled to Alexa 488 (Molecular Probes, Eugene, OR) was added at a 1:100 dilution in blocking buffer for 30 min. Actin was stained with rhodamine-phalloidin (5 µl per well; Molecular Probes), and the nuclei were stained with DAPI (Molecular Probes) for 30 min. Chamber slides were mounted with a coverslip in the presence of the antifade reagent DABCO (FUKA, Buchs, Switzerland) dissolved in 30% glycerol. Cells were analysed and photographed at ×60 magnification using a Nikon inverted microscope. For endogenous DOCK180 localization, NIH3T3 cells were starved for 16 h prior to treatment with either DMSO or 50 µM LY294002, as indicated in the figure legend. The cells were subsequently treated or not with 10 ng ml −1 of PDGF for 20 min, fixed and stained as described above. The DOCK180 polyclonal antibody was used at a 1:75 dilution in the immunofluorescence analysis. For time-lapse microscopy, images were acquired on an Olympus microscope with an automatic stage performing the objective changes (Nomarski, confocal Green and confocal Red). Cells were photographed at ×40 magnification. The video reconstitution of the images was created in Metamorph.
Cell migration assays. LR73 cells were transfected and prepared as described above with the exception that a GFP plasmid (0.5-1 µg per well) was included in these experiments as a marker for transfected cells. A typical transfection consisted of a total of 2-2.5 µg of plasmid DNA (0.9 µg of DOCK180, 0.3 µg of ELMO1, 0.3 µg of CrkII and 0.5-1 µg of pEGFP), and the amount of total plasmid was always kept constant by adding empty vector. The migration assays were performed in modified Boyden chambers (COSTAR; 8 µm pore size). For haptotactic assays, the underside of the Boyden chambers were pre-coated with fibronectin (10 µg ml −1 ) for 2 h before being transferred to wells containing FBM-BSA. For chemotactic assays, the Boyden chambers were pre-coated on both sides with fibronectin (10 µg ml −1 ) and were transferred to wells containing FBM-BSA + 10% serum. To initiate the migration assays, 100,000 cells were added in the upper chambers of the Boyden chambers, in duplicate, and allowed to migrate for 4-6 h. Cells were then fixed in 4% paraformaldehyde for 10 min, stained with DAPI and the remaining cells in the upper chambers were mechanically removed using cotton swabs. The membranes were mounted on coverslips and the GFP-and DAPI-positive cells that had migrated to the underside of the membranes were photographed (×40; inverted Nikon microscope) and counted. At least three independent fields per membrane were analysed in each sample. One-way analysis of variance (ANOVA) and All Pairwise Multiple Comparison Procedures (Holm-Sidak method) were performed for statistical analysis using the SygmaStat 3.1 software package. Typically, n = 6 for each data set, alpha level was 0.05 and a normality test was performed to ensure normal data distribution in each experiment. The transfection efficiency was monitored by re-plating an aliquot of the cells from each condition on fibronectin-coated slides for 4 h. Aliquots were also analysed by western blotting to monitor protein expression levels.
Lipid-binding assays. His-tagged DHR-1 constructs in pET28a were expressed in the BL21 strain and the induced cell lysates were mixed with a Nickel-Agarose matrix (Sigma). Bound material was washed extensively with 10 column volumes of Tris-HCl pH 8.0, 0.5 M KCl, 20 mM imidazole and 2 column volumes of TrisHCl pH 8.0, 1 M KCl prior to elution in Tris-HCl pH 8.0, 100 mM KCl, 300 mM imidazole. The GST PH domain of BTK was purified on glutathione-sepharose (GibcoBRL, Gaithersburg, MD) beads and eluted in PBS/10 mM glutathione at pH 8.0, as recommended by the manufacturer. Fractions containing the purified proteins were pooled and the amounts of proteins were immediately quantified by SDS-PAGE/Coomassie staining, using BSA as a standard. Approximately 5 µg of the proteins were then diluted in 500 µl of PtdInsP beads binding buffer (10 mM HEPES pH 7.5, 150 mM NaCl, 0.25% NP-40). The diluted proteins were mixed with 20 µl of packed beads coated with the various lipids and incubated at room temperature for 1 h. The beads were then washed three times in binding buffer. The bound material was subjected to SDS-PAGE and detected by immunoblotting using the anti-His or anti-GST antibodies. Alternatively, the proteins were used to probe lipid-spotted Hybond C-Extra membranes, as previously described 31 . Bound proteins were detected by immunoblotting with the anti-His-and anti-GST-specific antibodies.
Cell fractionation. Cell fractionation was performed as described previously 42 . Briefly, 1 × 10 6 HEK293-T cells that had been transfected with the indicated plasmids were harvested by gently suspending in PBS and the suspension was centrifuged at 800g for 5 min to collect the cells. The cells were then suspended in 300 µl of Buffer A (20 mM Tris-HCl pH 7.5, 150 mM NaCl, 5 mM NaF, 1 mM Na 3 VO 4 , Complete protease inhibitors), subjected to a single freeze/thaw cycle in liquid nitrogen and a 37 °C water bath followed by centrifugation at 16,000g for 10 min. The supernatant was collected and termed the 'cytosolic' fraction. The pellet was washed with 500 µl of Buffer A before extraction with Buffer A + 1% Triton X-100. The clarified supernatant was termed the 'membrane' fraction. Equal amounts of proteins (typically between 15-20 µg) were resolved by SDS-PAGE and the proteins of interest were analysed by immunoblotting with specific antibodies. C-19) . The same extracts were subjected to successive rounds of immunoprecipitation with the DOCK180 antibody, as indicated. The DOCK180 depleted lysates were immunoprecipitated with an anti-ELMO (c) or anti-GFP antibodies (d) to recover any remaining endogenous and exogenous ELMO-proteins, respectively. The various immunoprecipitates were analyzed by immunoblotting with anti-ELMO, anti-GFP and anti-DOCK180 (C19) antibodies, as indicated (c-d). Exogenously expressed DOCK180 and ELMO proteins extracted in RIPA buffer, from the post NP-40 debris, are also found in the same complex (e). In this experiment, the RIPA lysate was diluted 3-fold with NP-40 buffer and DOCK180 was immunoprecipitated. The coprecipitation of ELMO-GFP was verified by immunoblotting with an anti-GFP antibody. f) DOCK180 localizes at the plasma membrane. Serum-starved LR73 cells that had been transfected with DOCK180 WT, ELMO and CrkII were detached and plated on fibronectin-coated cover slips for 60 min in the absence of serum prior to fixing. Cells were analyzed as in (a). 
Figure S4
The DOCK180∆DHR-1+PH chimeric protein promotes Rac GTP-loading and interaction with ELMO1 and CrkII to the same extent as wild-type DOCK180. a) The PH domain of Bmx/Etk interacts with PtdIns(3,4,5)P 3 . Recombinant GST Bmx/Etk PH domain was purified and subjected to binding assays with PtdIns-or PtdIns(3,4,5)P 3 -coated beads. The bound PH domain was detected by immunoblotting with an anti-GST-HRP antibody. b) LR73 cells were transfected with the indicated plasmids and the GTP-loading status of Rac was analyzed by affinity precipitation with the PBD domain of PAK immobilized glutathione-sepharose beads (upper panel). As a loading control for Rac and to verify the expression of each construct, 20 µl of the lysates were analyzed by immunoblotting with antibodies against Rac, DOCK180 (C19) and Myc. c) DOCK180∆DHR-1+PH forms a trimolecular complex with ELMO1 and CrkII. LR73 cells were transfected with the indicated plasmids and Triton X-100 lysates were immunoprecipitated with an antibody against the Myc-epitope. Coprecipitation of the various DOCK180 proteins and ELMO1-GFP, in addition to the verification of equal CrkII precipitation, was examined by immunoblotting with antibodies against DOCK180 (C19), GFP and Myc, respectively (left panels). The expression of each construct was analyzed by immunoblotting 10 µg of the Triton X-100 lysates with antibodies against DOCK180 (C19), GFP and Myc, respectively (right panels).
Movie S1 GFP-ELMO localizes to the membrane ruffles in spreading LR73 cells. LR73 cells expressing GFP-ELMO, FLAG-DOCK180 and Myc-CrkII were plated on fibronectin, and the localization of GFP-ELMO1 during cell elongation was studied by acquiring, every minute for 135 min, confocal green (top right panel) and bright field/Nomarski (top left panel) images. In the bottom left panel, an overlay of the Nomarski and confocal green fields is shown. Movie S2 RFP-ELMO1 colocalizes with a probe for PtdIns (3, 4, 5) P3 (the GFP-BTK-PH domain) in vivo. COS-7 cells expressing RFP-ELMO1, FLAG-DOCK180 and Myc-CrkII together with the GFP-BTK-PH domain were allowed to adhere for 1 h on fibronectin prior to analysis. An enrichment and colocalization of RFP-ELMO1 and GFP-BTK-PH in membrane ruffles at the leading edge (10 min analysis with images acquired every 0.5 min) were observed (t=0-4 sec on the Video S2). The same cells were subsequently stimulated with EGF (100 ng/ml) for 10 min, resulting in the formation of ruffles throughout the membrane (t=5-9 sec on the Video S2). Colocalization of RFP-ELMO1 and GFP-BTK-PH was observed at these sites. The top left panel shows the images obtained for RFP-ELMO1 (confocal red) and the bottom left panel shows the images acquired for the GFP-BTK-PH (confocal green). In the top right panel, an overlay of the confocal red and green images is shown.
